DN24-02, an investigational active cellular immunotherapy (ACI) ACTIVE CELLULAR IMMUNOTHERAPY (ACI)A therapeutic platform that uses a patient’s own cells to stimulate an immune response against cancer.Close targeted at the HER 2/neu receptor, is currently being evaluated in a Phase 2 PHASE 2 CLINICAL TRIALA study to assess the preliminary efficacy of a treatment at the dose and dosing schedule determined in the Phase 1 trial and to provide further safety information(for example, whether it shrinks a tumor or improves blood test results).Close clinical trial called Neu-ACT for the treatment of HER2+ urothelial carcinoma. DN24-02 has completed two Phase 1 Phase 1 Clinical TrialThe first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, Phase 1 trials usually include only a small number of patients.Closeclinical trials for the potential treatment of patients with breast, ovarian and colorectal solid tumors expressing HER2/neu. This ACI product candidate targets the HER2/neu antigen AntigenA substance that causes the body's immune system to react. This reaction often involves production of antibodies. For example, the immune system's response to antigens that are part of bacteria and viruses helps people resist infections. Cancer cells have certain antigens that can be found by laboratory tests. Some of these may be important in cancer diagnosis and in watching response to treatment.Closeand utilizes the same proprietary antigen-engineering technology as PROVENGE.
Dendreon has in-licensed 2 additional antigen targets, carbonic anhydrase IX (CA9) and carcinoembryonic antigen (CEA), for the development of ACI candidates. Product candidates targeted at CA9 are in preclinical development for the treatment of kidney, colon, and cervical cancer. Product candidates targeted at CEA are in preclinical development for the treatment of breast, lung, and colon cancer.
ACI Product Candidate Clinical Trials:
N10-1 (called Neu-ACT)